NasdaqGS:ABUS

Stock Analysis Report

Executive Summary

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Arbutus Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.2%

ABUS

3.1%

US Biotechs

0.4%

US Market


1 Year Return

-79.2%

ABUS

2.3%

US Biotechs

11.4%

US Market

Return vs Industry: ABUS underperformed the US Biotechs industry which returned 2.3% over the past year.

Return vs Market: ABUS underperformed the US Market which returned 11.4% over the past year.


Shareholder returns

ABUSIndustryMarket
7 Day-4.2%3.1%0.4%
30 Day-42.3%1.4%0.3%
90 Day-50.6%1.1%-1.2%
1 Year-79.2%-79.2%3.2%2.3%13.9%11.4%
3 Year-72.2%-72.2%18.8%14.6%47.2%37.6%
5 Year-94.8%-94.8%-0.9%-5.7%62.4%44.6%

Price Volatility Vs. Market

How volatile is Arbutus Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arbutus Biopharma undervalued compared to its fair value and its price relative to the market?

1.54x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABUS's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABUS's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABUS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ABUS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ABUS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ABUS is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Arbutus Biopharma forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

11.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABUS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABUS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABUS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABUS's revenue (4.3% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: ABUS's revenue (4.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABUS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Arbutus Biopharma performed over the past 5 years?

-12.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ABUS is unprofitable, and losses have increased over the past 5 years at a rate of -12.5% per year.

Accelerating Growth: Unable to compare ABUS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.9%).


Return on Equity

High ROE: ABUS has a negative Return on Equity (-54.29%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ABUS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ABUS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Arbutus Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: ABUS's short term assets ($99.6M) exceeds its short term liabilities ($8.8M)

Long Term Liabilities: ABUS's short term assets (99.6M) exceeds its long term liabilities (19.3M)


Debt to Equity History and Analysis

Debt Level: ABUS is debt free.

Reducing Debt: ABUS had no debt 5 years ago.


Balance Sheet

Inventory Level: ABUS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if ABUS's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABUS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABUS has sufficient cash runway for 1.225539 years if free cash flow continues to reduce at historical rates of -3.7% each year.


Next Steps

Dividend

What is Arbutus Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ABUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABUS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ABUS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABUS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABUS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Arbutus Biopharma's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Bill Collier 0

0.3yrs

Tenure

0

Mr. William H. Collier has experience as a senior executive in the pharmaceutical industry and previously served as President and General Manager, North America at ViiV Healthcare. At ViiV he led the indus ...


Management Age and Tenure

1.3yrs

Average Tenure

59.5yo

Average Age

Experienced Management: ABUS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

1.0yrs

Average Tenure

54yo

Average Age

Experienced Board: ABUS's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Dave Hastings (58yo)

    CFO & Chief Accounting Officer

    • Tenure: 1.3yrs
    • Compensation: US$1.45m
  • R. Mackay-Dunn (68yo)

    Secretary

    • Tenure: 9.4yrs
  • Mike Sofia (61yo)

    Chief Scientific Officer

    • Tenure: 4.8yrs
    • Compensation: US$846.83k
  • Mike McElhaugh (45yo)

    Chief Business Officer

    • Tenure: 0.8yrs
  • Liz Howard (65yo)

    Executive VP

    • Tenure: 3.6yrs
    • Compensation: US$740.05k
  • Gaston Picchio (56yo)

    Chief Development Officer

    • Tenure: 1yrs
    • Compensation: US$1.78m
  • Pam Murphy

    Investor Relations Consultant

    • Tenure: 0yrs
  • Bill Collier

    President

    • Tenure: 0.3yrs

Board Members

  • Richard Henriques (63yo)

    Independent Non-Executive Director

    • Tenure: 4.6yrs
    • Compensation: US$188.23k
  • Dan Burgess (57yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$180.23k
  • Keith Manchester (50yo)

    Independent Non-Executive Director

    • Tenure: 4.6yrs
    • Compensation: US$157.72k
  • Adrian Di Bisceglie

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Charlie Rice

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jim Meyers (54yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: US$170.96k
  • Bill Symonds (51yo)

    Chairman of Scientific Advisory Board

    • Tenure: 1yrs
  • Frank Torti (40yo)

    Independent Chairman of the Board of Directors

    • Tenure: 0.9yrs
    • Compensation: US$162.35k
  • Scott Biller (63yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Bill Collier

    President

    • Tenure: 0.3yrs

Company Information

Arbutus Biopharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arbutus Biopharma Corporation
  • Ticker: ABUS
  • Exchange: NasdaqGS
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$50.557m
  • Shares outstanding: 56.85m
  • Website: https://www.arbutusbio.com

Number of Employees


Location

  • Arbutus Biopharma Corporation
  • 701 Veterans Circle
  • Warminster
  • Pennsylvania
  • 18974
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABUSNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDMay 2007
I9DNDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2007

Biography

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in C ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/24 00:25
End of Day Share Price2019/10/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.